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Abstract: Glioblastoma (GBM) is the most common form of primary brain cancer in adults and
tissue biopsies for diagnostic purposes are often inaccessible. The postulated idea that brain cancer
cells cannot pass the blood–brain barrier to form circulating tumor cells (CTCs) has recently been
overthrown and CTCs have been detected in the blood of GBM patients albeit in low numbers.
Given the potential of CTCs to be analyzed for GBM biomarkers that may guide therapy decisions
it is important to define methods to better isolate these cells. Here, we determined markers for
immunomagnetic targeting and isolation of GBM-CTCs and confirmed their utility for CTC isolation
from GBM patient blood samples. Further, we identified a new marker to distinguish isolated
GBM-CTCs from residual lymphocytes.
Keywords: glioblastoma; circulating tumor cell (CTC); biomarker; blood; liquid biopsy; immunomagnetic
enrichment
1. Introduction
Glioblastoma (GBM) is the most common form of primary brain cancer in adults and one of the
most lethal forms of cancer; only 5% of patients survive five years [1]. Diagnosis requires surgery to
obtain tissue for standard histopathological processing, but the location of some tumors makes access
challenging [2]. Moreover, follow-up MRI scans can be difficult to interpret as to whether patients
have chemoradiation-related treatment changes such as pseudo-progression versus recurrent disease,
and timely clinical decision making may thus be hampered. Therefore, there is a critical need for new
methods to determine prognosis and identify biomarkers that guide therapy decisions in GBM.
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Circulating tumor cells (CTCs) are cancer cells that detach from the main tumor mass and
enter the bloodstream which may be associated with the metastatic process. Over the past 15 years,
clinical studies suggest that capture and enumeration of CTCs can provide important prognostic
information [3–5]; moreover, these cells can be isolated and analyzed for molecular biomarkers [6].
For many years, it had been argued that CTCs were not present in GBM patients, due to the rarity
of the development of the distant metastatic disease, and the belief that the inability of the cells to
egress across the blood-brain barrier created an insurmountable difficulty. However, in 2014, CTCs
were discovered in the bloodstream of GBM patients by three research teams. The proportion of
CTC-positive patients ranged from 21% to 72% (29/141, 13/33 and 8/11), generally with low CTC counts.
On this basis, it was proposed that CTCs could provide an alternative method of accessing GBM cells,
compared to surgery, for analysis of relevant biomarkers [7].
The methods for detecting GBM-CTCs in these seminal studies involved separation from red
blood cells by gradient centrifugation, alone or followed by CD45-targeted cell depletion to exclude
white blood cells, combined with immunocytostaining for GBM specific markers, mainly glial fibrillary
acidic protein (GFAP), or fluorescence in situ hybridization (FISH) probing of the chromosome 8
centromere to determine aneuploidy. Alternatively, viral transduction of green fluorescent protein
expressed under the regulation of the telomerase (hTERT) promoter to identify cancer cells was used
for CTC detection [8–11]. However, these methods of CTC detection may not be ideal, as millions of
cells need to be screened for GBM markers by microscopy, or negative enrichment may cause loss
of already rare CTCs due to potential antibody cross-reactions or physical co-segregation of CTCs
amongst blood cells in the process. Further, current markers used to identify GBM-CTCs lack specificity,
and clearly distinguishing CTCs from residual rare or common blood cells may either be associated
with lack of specificity causing relatively high background staining, or potential of false-positive
detection [10]; or lack of sensitivity due to marker heterogeneity in GBM cells, meaning some CTCs
may be missed [8,12]. A more recent study used size exclusion to successfully detect GBM-CTCs and
less frequently GBM-CTC clusters [13]; size exclusion CTC enrichment relies on tumor cells being
larger than residual blood cells which is common, but not always the case.
Here, we tested a range of antibodies against candidate GBM cell surface proteins to develop a
positive immunomagnetic GBM-CTC isolation protocol. We further screened for other GBM-CTC
identification markers which established one additional marker useful for brain cancer CTC
identification. Using this novel method, we have successfully isolated GBM-CTCs from GBM
patient blood samples.
2. Materials and Methods
2.1. Cell Lines
The GBM cell lines A172, LN-229, T98G, U251 and U87 were cultured in DMEM media (Lonza,
Basel, Switzerland) containing 10% foetal bovine serum (FBS) (Interpath, Melbourne, Australia), 4 mM
L-glutamine (Sigma) and 20mM HEPES (Sigma) at 37 ◦C with 5% atmospheric CO2. All cell lines
were STR-authenticated (AGRF, Melbourne, Australia) and tested as free of mycoplasma using the
MycoAlert kit (Lonza, Basel, Switzerland).
2.2. Patients
Thirteen patients with a diagnosis of primary brain cancer were recruited from Liverpool Cancer
Therapy Centre. Clinical information was sourced from patient medical records. Patient characteristics
are summarized in Table 1. Per sample, 3x 9ml EDTA vacutubes (Greiner Bio-One, Frickenhausen,
Germany) of peripheral blood were drawn. Blood samples from healthy individuals were analyzed as
controls. The study was undertaken with written consent and approval of the South Western Sydney
Human Ethics Committee (HREC/13/LPOOL/158).
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Table 1. Patient characteristics.
Patient Gender Age # Grade Histology Tumour Location ECOG 1 ECOG 2
1 M 61 4 GBM Left tempoparietalregion 1 0
2 M 47 4 GBM Right parietal lobe 0 1
3 M 32 4 GBM Left frontal lobe 0 1
4 F 30 4 GSM * Right frontoparietalregion 0 0
5 F 47 4 GBM Right temporal lobe 1 0
6 M 75 4 GBM Cerebellum 1 1
7 M 36 4 GBM Right parietal lobe 0 1
8 M 33 4 GBM Right frontal lobe 0 0
9 M 68 4 GBM Right temporal lobe 1 2
10 M 60 4 GBM Left frontal lobe 2 2
11 F 50 4 GBM Bifrontal region 0 3
12 F 71 4 GBM Left parietal lobe 1 2
13 M 83 4 GBM Right frontal lobe 1 1
M male; F female; * re-diagnosed as GSM (gliosarcoma); # at diagnosis; ECOG1 Eastern Cooperative Oncology
Group score pre-surgery, ECOG2 Eastern Cooperative Oncology Group score post-surgery.
2.3. Immunocytostaining
Cell lines: 1 × 105 cells were seeded on glass coverslips and grown for 72 hours at 37 ◦C before
immunocytostaining. For cell-surface protein probing, cells were fixed using 3.7% formaldehyde
(VWR, Radnor, USA), blocked in 10% FBS in PBS for 10min, and incubated with primary anti-human
MCSP antibody (αMCSP) and anti-human MCAM antibody (αMCAM) for 1 hour (see Table S1 for
antibody details and dilutions). The cells were washed three times with PBS and incubated for 30 min
with secondary anti-mouse IgG AlexaFluor488 antibodies (Thermo Fisher), washed twice with PBS
and once with distilled H2O. The coverslips were mounted on slides with mounting media containing
Hoechst-dye (Fluxion, San Francisco, CA, USA ).
For cytoplasmic protein detection cells were permeabilized after fixing using 0.2% Triton-X in PBS
for 10 minutes (Sigma-Aldrich, St. Louis, USA). The cells were then incubated for 1 hour with a primary
antibody, anti-human GFAP (αGFAP), followed by AF555 conjugated anti-rabbit-IgG antibody probing
(Thermo Fisher), FITC-conjugated anti-human glutamate aspartate transporter (GLAST) (αGLAST)
(Novus Biologicals, Centennial, CA, USA) or both (see Table S2 for dilutions). The coverslips were
mounted using Hoechst-dye containing mounting media (Fluxion) and were visualized on a LSM 800
laser-scanning confocal microscope with AiryScan (Carl Zeiss, Oberkochen, Germany) or Olympus
BX53 microscope (Olympus, Notting Hill, Australia).
2.4. Flowcytometry
Cells were seeded at 50% confluency in tissue culture flasks cultured for 2 days and harvested
using 0.5mM EDTA in PBS to maintain cell surface proteins. Cells were blocked with 10% FBS in PBS
and probed sequentially with primary and secondary antibodies for 30 and 20 minutes respectively
(Table S1) and resuspended in 300 µl of PBS for flowcytometry (FACS) analysis (FACS Canto II
Cell Analyzer, BD Biosciences). Flowing Software 2.5.1 was used for analysis (Turku Centre for
Biotechnology, Turku, Finland). Antigen detectability of ≤ 3 ± 2% of a cell line’s cell population was
considered negative in regards to suitability as the isolation target.
2.5. Immunomagnetic Cell Isolation
Immunomagnetic beads, with a Rare Cell Isolation Kit (Fluxion, San Francisco, USA), were
incubated with αMCAM or αMCSP antibodies for conjugation according to the manufacturer’s
protocol (see Table S1 for antibody concentrations). For basic confirmation of suitability for GBM cell
isolation n = 100 LN-229 cells were suspended in 800 µL binding buffer (Fluxion), and, after addition of
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40 µL FC buffer (Fluxion) and either 30 µL αMCAM antibody coupled beads, 30 µL αMCSP antibody
coupled beads or 30 µL of each, incubated for 90 minutes at 4 ◦C on a rotating platform. Cells were then
isolated by magnetic force using a magnetic rack, washed three times with binding buffer, fixed with
4% formaldehyde in PBS, washed, immunocytostained for GBM markers and Hoechst and enumerated
using the CellCelector (ALS) for fluorescent imaging.
Patient and healthy donor blood samples were processed within 24-hours using lymphoprep
and Sepmate tubes (Stemcell Technologies, Vancouver, Canada) to separate the peripheral blood
mononuclear cells (PBMCs) according to the manufacturer’s instructions. PBMCs derived from
27 mL blood each were washed once in PBS and resuspended in 800 µL binding buffer and incubated
with 30 µL αMCAM coupled and 30 µL αMCSP coupled magnetic beads. Cells were incubated for
90 minutes at 4 ◦C on a a rotating platform and then loaded into primed IsoFlux cartridges for CTC
enrichment using the IsoFlux CTC isolation platform with the standard isolation protocol (Fluxion).
Enriched CTCs samples were fixed with 3.7% formaldehyde in PBS before immunocytostaining.
2.6. Immunocytostaining of Circculating Tumor Cells
Anti-human CD45-AF647 conjugate (Thermo Fisher) was used to stain residual blood cells; before
permeabilization (0.2% Triton X-100 in PBS) and incubation with rabbit αGFAP combined with AF555
anti-rabbit IgG secondary probing and FITC-conjugated αGLAST antibody, after two washes cells
were placed on slides with Hoechst dye in the mounting media (See Table S2 for antibody dilutions).
Stained CTCs were visualized and enumerated using the CellCelector fluorescent microscope (ALS,
Jena Germany).
3. Results
3.1. Cell Surface Protein Expression on Glioblastoma Cells
To identify appropriate cell surface targets for immunomagnetic isolation of GBM cells, a number
of cell surface proteins identified from literature searches were screened with appropriate antibodies
for the presence on a cohort of GBM cell lines by FACS analysis (Table 2, Table S1). Antibodies
that demonstrated limited reactivity to GBM cells (≤3% ± 2% of the cell population positive) were
disregarded for isolation. Those that reacted with GBM cells were further tested for antibody
cross-reactivity with healthy donor peripheral blood mononucleated cells (PBMCs); considerable
PBMC cross-reactivity suggested unsuitability as potential tools for immunomagnetic GBM-CTC
isolation due to expected and undesirable co-capture of PBMCs. The remaining antibodies against
promising target proteins were further evaluated by immunocytostaining.
Table 2. Cell surface protein detection on cell lines by flowcytometry.
Detectable [% of Cells]
Antigen A172 LN-229 T98G U87 U251 PBMCs
MCAM 51.0 ± 3.6 94.6 ± 1.7 64.1 ± 5.4 67.8 ± 4.9 42.7 ± 0.1 -
MCSP 80.4 ± 4.1 92.1 ± 2.6 - 89.3 ± 13.7 - -
N-Cadherin 70.2 ± 13.8 55.3 ± 0.6 17.1 ± 0.6 - 94.3 ± 3.3 -
EGFR 96.8 ± 0.3 78.1 ± 1.3 29.2 ± 0.4 11.2 ± 3.2 34.5 ± 8.3 -
CD271 5.9 ± 0.1 57.3 ± 0.4 8.6 ± 10.5 - - -
A2B5 - - - - n/d n/d
-: Values ≤ 3.0 ± 2% were considered negative for purpose of isolation target candidates; n/d: not determined due to
early elimination of isolation candidate.
Since neural cells and melanocytes are embryologically related (both originate developmentally
from the neural crest) [14], we included antibodies against the melanoma-associated chondroitin sulfate
proteoglycan (MCSP) and melanoma cell adhesion molecule (MCAM) in our screen. We have previously
shown both proteins to be suitable targets for immunomagnetic melanoma CTC isolation [15]. After
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the exclusion of other candidates, MCSP and MCAM were identified as the most promising cell surface
protein targets for immunomagnetic isolation of GBM cells. MCSP was detected on up to 92% of the
cell populations of GBM cell lines tested with high proportions of LN-229 (92%), U87 (89%) and A172
(80%) cells expressing the antigen. However, both T98G and U251 cells were MCSP negative. MCAM
was expressed on 43%–95% of the cells of all cell lines. Very high proportions of LN-229 (95%), most
U87 (68%) and T98G (64%) cells were positive for MCAM, while around half of A172 (51%) and U251
(43%) cell populations expressed MCAM (Table 2, Figure 1). Importantly, the anti-MCSP (αMCSP)
and anti-MCAM (αMCAM) antibodies showed negligible reactivity with PBMCs from healthy donors
(Table 2).
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GBM cell lines or strong cross-reactivity of the corresponding antibodies with PBMCs (Table S2, 
Figure S1). Notably, GFAP was in our hands not detected in any GBM cell line (data not shown). 
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Cell surface expression of CA (left) and CSP (right) was screened on the indicated cell
lines by immunocytostaining (specific protein detected in green FITC channel, while Hoechst staining
detects cell nuclei, erged i ages included) and flow cyto etry. Proportions of cell populations
expressing the indicated protein are stated fro at least n = 2 independent experi ents (as gated on
flowcyto etry data co paring the light grey protein-specific peak to isotype- atched IgG probing
(dark grey peak)). Representative histogra s included.
3.2. GBM-CTC Identification Markers
It is important to emphasize that CTC isolation methods usually deliver enrichment of CTCs
rather than complete isolation, therefore further CTC identification to distinguish them from residual
lymphocytes is generally required. Therefore, we also screened for alternate markers for the
identification of GBM-CTCs in addition to GFAP, which is known to be heterogeneously expressed in
GBM [12]. Immunocytostaining was used on our cohort of brain cancer cell lines for a range of proteins
expressed in GBM (Table S2). The GLAST was found to be expressed in all GBM cell lines (~98–100%
of the cell populations). Moreover, only negligible cross-reactivity was found between the αGLAST
antibody and healthy donor PBMCs (Figure 2), suggesting GLAST may be a suitable identification
marker for brain cancer CTCs. Other potential markers had either poor expression in GBM cell lines or
strong cross-reactivity of the corresponding antibodies with PBMCs (Table S2, Figure S1). Notably,
GFAP was in our hands not detected in any GBM cell line (data not shown).
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3.3. Immunomagnetic Capture of GBM Cells
To confirm that both MCAM and MCSP were suitable immunomagnetic targets for GBM cell
isolation, we used LN-229 cells, due to MCAM and MCSP co-expression as determined by flow
cytometry. Individually, targeting MCAM for cell isolation performed slightly better than MCSP
targeting (26% versus 20% recovery) but there was a clear advantage of targeting both antigens in
combination, which captured approximately 50% LN-229 cells (Figure 3).
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Figure 3. GBM cell capture. i r . .
The indicated antibodies were used to immunomagnetically recover LN-229 cells. Data from at
least n = 2 independent experiments are presented. Horizontal error bars: mean range.
We then tested our method for GBM-CTC isolation on 15 blood samples from 13 patients (samples
from two patients were included at 2 independent time points approximately 3 months apart).
The amount of blood available for CTC isolation was 27 mL (3 × 9 mL) per patient. We successfully
isolated 1-8 CTCs from 60% (9/15) of GBM patient blood draws when targeting the combination of
MCAM and MCSP for CTC isolation (Figure 4A). Two-sided Fisher’s exact test established significance
(p-value = 0.0379) in isolating cells that are positive for GLAST and/or GFAP from GBM patients vs
healthy blood donors. Importantly, a comparison of CTC identification by GFAP and GLAST staining
across all patient samples confirmed that the combination of both identification antibodies increased
CTC detection (Figure 4B,C).
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Figure 4. CTC isolation from GBM patient blood. Fifteen 27 mL patient blood samples from 13
GBM patients (P1-P13) were analyzed for GBM-circulating tumor cells (CTCs) using combined
im unomagnetic targeting of MCAM and MCSP. CTCs were detected by αGFAP and αGLAST probing.
(A) CTC counts for 13 patients/15 samples (patients with repeat samples are indicated -2). The same
isolation protocol was used for 5 healthy donor blood samples (H1-H5) and detected no false positive
“CTCs”. (B) Typical identification of a CTC (arrow) by nuclear staining (Hoechst), GLAST (green)
and GFAP ( d) positivity as well as lack of CD45 (pseud color purple). (C) For the nine GBM-CTC
positive patient blood draws, he mean of CTC det cted by either αGFAP or αGLAST probing alone
or detected by double positivity is presented. Columns indicat the average and error bars standard
deviations. * indic tes signific nce (p ≤ 0.05).
No correlation betwe n CTC positivit t rogre sion-fr e survival or overall survival
was found in the small patient cohort (Figure 5).
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Figure 5. CTC status and survival.
CTC numbers were quantified for 13 patients and follow up progression-free survival (PFS) and
overall survival (OS) were determined for each patient and are presented for CTC positive (red) and
CTC negative patients (blue) as Kaplan–Meier graphs.
4. Discussion
The aim of this study was to develop a positive immunomagnetic enrichment strategy for
GBM-CTCs and improve identification markers for GBM-CTCs.
A cohort of neurological cell-specific, cell surface markers were considered less useful for CTC
isolation since there was no, the low or variable expression on cultured GBM cells or when the
expression on common blood cells was detected with the validated antibodies used in our study. While
most of the markers we screened had previously been detected by others on cultured GBM cells or
tissue (Tables S1 and S2), our inability to replicate some of these findings in our cultured GBM cells
may be due to factors such as different antibodies used, different protein levels between cultured cells
and GBM tissue or increasing heterogeneity of long term established cell cultures used in the various
laboratories. The most promising markers, MCAM and MCSP, have been successfully used by us and
others for the isolation of melanoma CTCs previously [15,16]. Since melanocytes originate from the
neural crest [14], the detection of GBM cells is not surprising. It is important to note however that
MCAM and MCSP were not equally well expressed on all tested GBM cell lines (proportion of positive
cell population, Figure 1). If such heterogeneity translates to patient-derived GBM-CTCs, GBM-CTCs
expressing low antigen would be captured less efficiently.
While immunomagnetic targeting of MCAM and MCSP proved independently successful for the
capture of LN-229 cells, the combination of both antibodies was superior for cell isolation. Additionally,
our previous data clearly show that the strategy of targeting both proteins together improved melanoma
CTC capture from patient blood [15]. Therefore, we used the same strategy for successful GBM-CTCs
enrichment from patient samples. CTC counts for our study were low, which is consistent with
reported GBM-CTC counts in other studies [8–10,13] and our immunomagnetic targeted CTC isolation
produces better CTC enrichment (ratio CTCs: residual blood cells) than some previous studies likely
to make certain down-stream analyses easier. This is the first method positively immune-targeting
GBM-CTCs for enrichment. Recently, another study did achieve GBM-CTC enrichment by conjugating
a malaria protein, VAR2CSA, to magnetic beads. VAR2CSA has a high affinity to chondroitin sulfate
proteoglycans proposed to be uniquely expressed on cancer cells. The study isolated CTCs in
comparable numbers to our study [17]. Of note, MCSP belongs to the chondroitin sulfate proteoglycan
protein family and our data confirm high expression on some GBM cell lines but total lack on others,
highlighting that targeting more than one cell surface protein should be considered advantageous for
GBM-CTC isolation.
In our hands, markers such as nestin, previously suggested as suitable for GBM-CTC detection,
were less satisfactory [9]; this may have been due to a different anti-nestin antibody (raised in rabbit)
used here, due to compatibility with our isolation antibodies. Since our isolation antibodies were
raised in mice, a mouse-anti-nestin antibody would have produced strong cross-reactivity with
magnetic beads. Our nestin probing showed positivity in GBM cells but also PBMCs (Figure S1).
Appl. Sci. 2020, 10, 3338 9 of 11
Nevertheless, we identified one marker to better distinguish GBM-CTCs from residual lymphocytes.
GLAST, supposedly present on all brain cells, is a transporter protein, and is normally cell-membrane
localized, but can be internalized and predominantly found in the nucleus in GBM tissue and cultured
GBM cells [18]. Our GBM cell staining confirmed nuclear GLAST for all but LN-229 cells (Figure 2).
The recognition of anti-GLAST as an additional identification antibody is important, since the commonly
used GFAP identification marker protein is not present in all GBM cells [12]. Interestingly, in our
hands, immunocytostaining did not detect GFAP in any of the GBM cell lines tested, whereas GLAST
was readily detected in all five GBM cell lines. However, GFAP expression is reportedly often lost in
cultured cells, likely via epigenetic silencing [19]; thus, our inability to detect it in cell lines may be an
artifact of cell culture. Since GFAP probing was previously used to successfully identify GBM-CTCs by
others [8], we retained it as a CTC identification marker and successfully detected GFAP in patient
GBM-CTCs. Here, we confirmed heterogeneity for GFAP and GLAST expression in patient CTCs;
and showed that probing for both identification markers is significantly superior to only probing for
GFAP to identify GBM-CTCs (Figure 4C). Combining GFAP with GLAST for GBM-CTC detection can,
therefore, function as an additional validation marker for the GBM origin of these cells, as well as aid
in identifying more CTCs overall.
The major limitation of our study is the small patient cohort, which makes it premature to try
to establish a correlation between GBM-CTC counts and disease outcomes. To date, the overall
small investigated patient numbers in all relevant studies that tested for correlations of GBM-CTC
counts to sub-type of glioma, histological grade, pre- and post-surgical tumour burden, treatment
response, survival or pseudoprogression were challenging [8,9,11]. However, the advent of novel
techniques such as single-cell methodologies has enabled successful interrogation of even single
CTCs for clinical biomarkers, thus detecting even small CTC numbers that may provide a source
of biomarker detection [6]. Given the rarity of primary brain cancer CTCs, obtaining larger blood
volumes such as 50 mL would be desirable and still remain less invasive than surgical biopsy or
lumbar puncture cerebral spinal fluid (CSF) collection. Another, technical limitation of this study is
that we based screening for potential immunomagnetic cell surface targets on cultured monolayer
cells only. As discussed, cell culture may change protein expression patterns and thus reflect less truly
expression of proteins for cancer tissue or, important for this study, CTCs. While including examination
of cell surface markers in tissue and potentially cultured cells that grow in spheres may have revealed
additional immunomagnetic targets, their true value for CTC isolation may only be shown by direct
comparison for CTC isolation from patient samples; and the limitation is the amount of patient blood
that can be drawn to allow for multiple comparisons. Here we tested two immunomagnetic isolation
target candidates and have shown that GBM CTCs are captured targeting these markers. This could
become a benchmark to test other isolation target candidates against in the future.
5. Conclusions
We have established an immunomagnetic method for targeted isolation of GBM-CTCs and
identified a novel GBM-CTC identification marker. GLAST probing can complement GFAP probing for
improved GBM-CTC identification. Our GBM-CTC isolation and identification methods are a viable,
relatively simple strategy for detecting GBM-CTCs from patient samples. Since repeated brain cancer
biopsies from surgery or even repeated CSF collection are not clinically justified, it is possible that
blood-based CTC analysis may become a feasible way to access biomarker information for optimal
GBM patient management.
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